# Aclarion, Inc.: overview

ACON · Nasdaq · CIK 1635077 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/acon.md) · [Financials](/companies/acon/financials.md) · [Filings](/companies/acon/filings.md) · [Insiders](/companies/acon/insiders.md)

Latest reported revenue: [$25.2k](/filings/0001683168-26-006026.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001683168-26-006026).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [14.4](/filings/0001683168-25-008169.md) | [10.2 d](/filings/0001683168-26-001986.md) | [19.0](/filings/0001683168-26-003822.md) | [19.3](/filings/0001683168-26-006026.md) | [18.9](/filings/0001683168-25-008169.md) | [18.5 d](/filings/0001683168-26-001986.md) | [21.1](/filings/0001683168-26-003822.md) | [25.2](/filings/0001683168-26-006026.md) |
| Gross margin | % | [(48.1%)](/filings/0001683168-25-008169.md) | [(100.9%) d](/filings/0001683168-26-001986.md) | [(23.6%)](/filings/0001683168-26-003822.md) | [26.6%](/filings/0001683168-26-006026.md) | [23.2%](/filings/0001683168-25-008169.md) | [9.7% d](/filings/0001683168-26-001986.md) | [17.7%](/filings/0001683168-26-003822.md) | [32.9%](/filings/0001683168-26-006026.md) |
| Operating margin | % | [(8995.3%)](/filings/0001683168-25-008169.md) | [(17652.7%) d](/filings/0001683168-26-001986.md) | [(7856.0%)](/filings/0001683168-26-003822.md) | [(8988.6%)](/filings/0001683168-26-006026.md) | [(9666.2%)](/filings/0001683168-25-008169.md) | [(10785.2%) d](/filings/0001683168-26-001986.md) | [(14129.3%)](/filings/0001683168-26-003822.md) | [(11503.2%)](/filings/0001683168-26-006026.md) |
| Net margin | % | [(9482.7%)](/filings/0001683168-25-008169.md) | [(19444.6%) d](/filings/0001683168-26-001986.md) | [(10728.4%)](/filings/0001683168-26-006026.md) | [(8285.9%)](/filings/0001683168-26-006026.md) | [(9008.0%)](/filings/0001683168-25-008169.md) | [(10223.2%) d](/filings/0001683168-26-001986.md) | [(13498.5%)](/filings/0001683168-26-006026.md) | [(10899.5%)](/filings/0001683168-26-006026.md) |
| Diluted EPS | $ per share | [(1321.49)](/filings/0001683168-25-008169.md) | not reported | [(9.32)](/filings/0001683168-26-003822.md) | [(2.75)](/filings/0001683168-26-006026.md) | [(2.93)](/filings/0001683168-25-008169.md) | not reported | [(1.34)](/filings/0001683168-26-003822.md) | [(1.12)](/filings/0001683168-26-006026.md) |
| Free cash flow | $k | [(1,056) d](/filings/0001683168-25-008169.md) | [(928) d](/filings/0001683168-26-001986.md) | not reported | not reported | [(1,168) d](/filings/0001683168-25-008169.md) | [(1,641) d](/filings/0001683168-26-001986.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [60.3](/filings/0001683168-23-004066.md) | [60.4](/filings/0001683168-24-001821.md) | [75.4](/filings/0001683168-25-002351.md) | [45.7](/filings/0001683168-26-001986.md) | [75.7](/filings/0001683168-26-001986.md) |
| Gross margin | % | [(14.7%)](/filings/0001683168-23-004066.md) | [(8.0%)](/filings/0001683168-24-001821.md) | [(0.4%)](/filings/0001683168-25-002351.md) | [(85.2%)](/filings/0001683168-26-001986.md) | [9.0%](/filings/0001683168-26-001986.md) |
| Operating margin | % | [(4897.9%)](/filings/0001683168-23-004066.md) | [(9201.2%)](/filings/0001683168-24-001821.md) | [(6466.5%)](/filings/0001683168-25-002351.md) | [(12057.2%)](/filings/0001683168-26-001986.md) | [(9312.5%)](/filings/0001683168-26-001986.md) |
| Net margin | % | [(8210.5%)](/filings/0001683168-23-004066.md) | [(11694.4%)](/filings/0001683168-24-001821.md) | [(6513.4%)](/filings/0001683168-25-002351.md) | [(15293.8%)](/filings/0001683168-26-001986.md) | [(9551.9%)](/filings/0001683168-26-001986.md) |
| Diluted EPS | $ per share | [(6.58)](/filings/0001683168-23-004066.md) | [(19.61)](/filings/0001683168-24-001821.md) | [(79782.00)](/filings/0001683168-25-002351.md) | [(7478.90)](/filings/0001683168-26-001986.md) | [(13.61)](/filings/0001683168-26-001986.md) |
| Free cash flow | $k | not reported | not reported | [(3,647)](/filings/0001683168-25-002351.md) | [(5,277)](/filings/0001683168-26-001986.md) | [(7,186)](/filings/0001683168-26-001986.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/acon/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $56.1k | 19,480 |  | New +19,480 |
| [CAPTRUST FINANCIAL ADVISORS](/funds/1512024.md) | 2026-06-30 | $49.1k | 17,059 |  | Added +2,500 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $46.2k | 16,028 |  | New +16,028 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $44.2k | 15,355 |  | New +15,355 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $34.9k | 12,128 |  | Reduced −19,087 |
| [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $31.8k | 11,038 |  | New +11,038 |
| [BANK OF MONTREAL /CAN/](/funds/927971.md) | 2026-06-30 | $28.8k | 10,000 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $19.5k | 6,782 |  | Unchanged |
| [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $14.4k | 5,000 |  | Reduced −29,945 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $5.7k | 1,968 |  | Reduced −7,679 |

## Recent filings

[All 275 filings](/companies/acon/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 09:00 ET | [10-Q](/filings/0001683168-26-006026.md) | Quarterly report, period 2026-06-30 | 0001683168-26-006026 |
| 2026-06-04 | 16:49 ET | [8-K](/filings/0001683168-26-004565.md) | 5.07 Shareholder vote results | 0001683168-26-004565 |
| 2026-05-13 | 16:30 ET | [10-Q](/filings/0001683168-26-003822.md) | Quarterly report, period 2026-03-31 | 0001683168-26-003822 |
| 2026-04-27 | 16:05 ET | [DEF 14A](/filings/0001683168-26-003236.md) | Proxy statement, period 2026-06-04 | 0001683168-26-003236 |
| 2026-04-22 | 09:00 ET | [8-K](/filings/0001683168-26-003124.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-26-003124 |
| 2026-03-19 | 16:15 ET | [8-K](/filings/0001683168-26-002024.md) | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-26-002024 |
| 2026-03-18 | 16:57 ET | [10-K](/filings/0001683168-26-001986.md) | Annual report, period 2025-12-31 | 0001683168-26-001986 |
| 2026-01-13 | 09:00 ET | [8-K](/filings/0001683168-26-000241.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-26-000241 |
| 2026-01-09 | 09:03 ET | [8-K](/filings/0001683168-26-000168.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001683168-26-000168 |
| 2025-11-12 | 06:20 ET | [10-Q](/filings/0001683168-25-008169.md) | Quarterly report, period 2025-09-30 | 0001683168-25-008169 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001683168-26-001986.md), filed Mar 18, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9663b53a-048a-4600-9626-ed55ea57f907)

## About the filer

- CIK: 1635077
- Tickers: ACON, ACONW
- Exchange: Nasdaq
- SIC code: 8071 Services-Medical Laboratories
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.